RBCC Nears Finalization of Partnership Agreement with Leading-Edge Pharmacogenomics Labs

  RBCC Nears Finalization of Partnership Agreement with Leading-Edge
  Pharmacogenomics Labs

Business Wire

NOKOMIS, Fla. -- March 6, 2013

Rainbow Coral Corp. (OTCBB: RBCC), a biotech company focused on delivering new
medical technologies and innovations, today reports its anticipation of
partnering with a cutting-edge genome-mapping facility in Houston in the next
few weeks.

The genetic testing sector is one of the fastest-growing segments of the
global biotech industry, with some market experts expecting it to reach $2.2
billion by 2017. The cutting-edge science of pharmacogenomics is a field of
study resulting from the Human Genome Project that seeks to help doctors
assess genetic variations in patients in order to create more effective,
optimized drug treatment plans.

RBCC sees it as the future of medicine.

“This is the next evolution in personalized medicine,” said RBCC CEO Patrick
Brown. “Important differences in drug metabolism and response from person to
person are often rooted in our genes. By studying a patient’s genotype,
doctors can eliminate the trial-and-error approach to tailoring a safer, more
efficient and more effective drug treatment plan.”

RBCC is turning its full attention to the exploration of new promising
opportunities now that the company will no longer be partnering with Amarantus
Biosciences, which has elected to pursue other opportunites. RBCC wishes
Amarantus much success moving forward, and remains open to future partnering
opportunities with the company.

In addition to its pharmacogenomics talks, RBCC is also currently working on a
joint venture agreement with a privately held drug delivery company that could
soon make local delivery of biologic agents and small molecules safer, more
effective and more convenient than ever before.

For more information on Rainbow BioSciences’ current projects, please
visitwww.rainbowbiosciences.com/investors.html.

Rainbow BioSciences will develop new medical and research technology
innovations to compete alongside companies such as Bristol Myers Squibb Co.
(NYSE:BMY),Biogen Idec Inc. (NASDAQ:BIIB), Abbott Laboratories (NYSE:ABT)
and Amgen Inc. (NASDAQ:AMGN).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The Company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visit www.RainbowBioSciences.com. For investment information and
performance data on the Company, please
visitwww.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.

Contact:

Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
info@rainbowcoral.com